Genentech submits sNDA for venetoclax in untreated AMLJuly 12, 2018Leukemia, Myelodysplasia, Transplantation
Oral arsenic/ATRA is noninferior to IV form in APMLJuly 10, 2018Leukemia, Myelodysplasia, Transplantation
Mutations may be detectable years before AML diagnosisJuly 10, 2018Leukemia, Myelodysplasia, Transplantation
Venetoclax with 5+2 chemo looks effective in older AML patientsJuly 9, 2018Leukemia, Myelodysplasia, Transplantation
Concomitant drugs may explain PEG-ASP liver toxicities in ALLJuly 2, 2018Leukemia, Myelodysplasia, Transplantation
PVd improved survival in lenalidomide-exposed myelomaJune 28, 2018Leukemia, Myelodysplasia, Transplantation
Anti-CD22 CAR T rescues kids with ALL after CD19 failureJune 17, 2018Leukemia, Myelodysplasia, Transplantation
FDA grants regular approval to venetoclax for CLL/SLLJune 8, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLLJune 8, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
MRD-negative status signals better outcomes in CAR T–treated ALLJune 5, 2018Immuno-oncologyLeukemia, Myelodysplasia, TransplantationImmunotherapyLymphoma & Plasma Cell Disorders
Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AMLJune 3, 2018Leukemia, Myelodysplasia, Transplantation
New regimens for youth with T-cell malignancies yield best outcomes yetMay 19, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Children with Down syndrome and ALL have good outcomes todayMay 11, 2018Leukemia, Myelodysplasia, Transplantation
5-year data show deepening response with ibrutinib in CLLMay 11, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
